Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Myosin Phosphatase Regulatory Pathways

Different Functions or Redundant Functions?

Thomas M. Lincoln
Download PDF
https://doi.org/10.1161/01.RES.0000255894.25293.82
Circulation Research. 2007;100:10-12
Originally published January 4, 2007
Thomas M. Lincoln
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • phosphorylation
  • calcium
  • cyclic GMP
  • smooth muscle

In many ways, the smooth muscle cell (SMC) has been at the forefront in defining cellular signaling pathways. For example, the initial description of agonist-dependent intracellular calcium ([Ca2+]i) transients was made on vertebrate vascular SMC using aqueorin as the indicator.1 Delineation of nitric oxide (NO) and cGMP signaling was first accomplished in smooth muscle.2,3 And more recently, insights into the general mechanisms of gene transcription that dictate phenotypic traits of cells are being defined by smooth muscle specific gene expression.4,5 It should come as no surprise then that the interactions among many signaling pathways in cells should be explained first in the SMC. Perhaps the reason for the central position of the SMC in defining paradigms in cellular biology is that there are well-defined physiologic end points amenable to measurement (ie, contractile force) and even better described and easily quantified biochemical pathways that underlie said physiologic end points (ie, myosin regulatory light chain phosphorylation).

From a historical perspective, the role of protein phosphorylation in smooth muscle contraction as a paradigm for cell signaling follows only that for the control of glycogen metabolism (see 6,7 for reviews). Increases in the levels of cytosolic [Ca2+]i initiate smooth muscle contraction by binding to the universal intracellular Ca2+ receptor protein, calmodulin (CaM), which in turn binds to and activates smooth muscle myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation serine-19 of the regulatory myosin light chain (MLC) thereby increasing cross-bridge cycling and the rate of tension development. Dephosphorylation of MLC is catalyzed by smooth muscle specific myosin light chain phosphatase (MLCP). Decreases in cytosolic [Ca2+]i and MLC dephosphorylation are considered salient events in smooth muscle relaxation. What has become apparent only within the last decade is the fact that these 2 processes, decreased [Ca2+]i and MLC dephosphorylation, can be, and most likely usually are, independent events and independently controlled. It now seems clear that the regulation of MLCP activity plays a prominent role in smooth muscle contraction.

In vertebrate smooth muscle, MLCP is heterotrimer consisting of a serine/threonine phosphatase catalytic subunit, classified as a PP1c δ isoform, a 110 to 130 kDa myosin binding regulatory subunit known as MYPT1, and a third subunit of approximately 20 kDa whose function has yet to be defined.8 A portion of the cellular pool of MLCP is physically anchored to the myosin fiber where it is believed that activation of the phosphatase requires a conformational change in MYPT1 that leads to greater access of the catalytic subunit to the phosphorylated MLC.9 MYPT1, in turn, exists as several spliced variants in smooth muscle which undergo significant changes in expression with differentiation, different types of SMC, and in pathophysiological settings.10,11 One variant in which a 31 nt exon is spliced into the sequence creates a stop codon that results in the shorter isoform being expressed. The “spliced out” isoform does not contain the 5′-upstream stop codon and results in a longer form being expressed. From the physiologic standpoint, the existence of these 2 isoforms is significant because the longer isoform contains a C-terminal leucine zipper/coiled-coiled domain (LZ+) capable of selectively binding protein kinases such as cGMP-dependent protein kinase (PKG).12,13

An appreciation for the role of MLCP in the regulation of MLC phosphorylation and smooth muscle contraction began with studies on “calcium sensitization” of contraction (see14 for review). These studies demonstrated that agonist-induced MLC phosphorylation and contraction of smooth muscle were apparent at relatively low concentrations of [Ca2+]i compared with phosphorylation and contraction initiated by membrane depolarization using elevated K+ solutions. Because agonists were known to activate receptors coupled to heterotrimeric G-proteins, the idea was put forth that (an) additional signaling pathway(s) was/were activated under agonist stimulation that resulted in calcium sensitization of contraction. Several protein kinase pathways were proposed to mediate calcium sensitization including protein kinase C (PKC), which is activated on agonist-dependent stimulation of phospholipase C (PLC), and the small molecular weight G-protein, RhoA, which activates Rho-activated kinase (ROK). It turns out that both pathways, the PLC-PKC and the RhoA-ROK, are involved in calcium sensitization. And both kinases appear to intersect by inhibiting MLCP. The question is: how do these kinases, and perhaps others, regulate MLCP activity?

As discussed by Dimopoulos et al,15 2 independent mechanisms exist in smooth muscle for the inhibition of MLCP that sustains MLC phosphorylation in the face of declining [Ca2+]i: phosphorylation of MYTP1 and phosphorylation of a smooth muscle specific PP1c inhibitor protein, CPI-17. Moreover, phosphorylation of these two proteins in response to ROK and PKC activation follow distinct time courses and appear to be dependent on the mobilization of Ca2+ from distinct pathways. Taking MYTP1 phosphorylation first, it has been known that contractile agonist-dependent activation of the RhoA/ROK pathway results in the phosphorylation of 2 distinct residues, threonine-696 and threonine-853 (numbering according to the mammalian sequence), on MYPT116,17; phosphorylation of both residues has been correlated with diminished phosphatase activity, but it is T853 phosphorylation that appears to be most specifically associated with specific ROK-induced phosphatase inhibition. Indeed, ROK catalyzes the phosphorylation of T853 more efficiently than T696, suggesting that the actual role of ROK-dependent T696 phosphorylation is more complex. It is now known that several different serine/threonine protein kinases such as ZIP kinase catalyze the T696 phosphorylation of MYPT1.18 What is not known is whether or not activation of ROK lies upstream of the activation of one or more of these kinases which in turn results in T696 MYPT1 phosphorylation and phosphatase inhibition. Of these the ZIP kinase is a particularly interesting candidate given that, like ROK, it is highly abundant in SMC.18

To turn attention to CPI-17, this protein belongs to the larger family (defined by function if not by homology) of low molecular weight protein serine/threonine phosphatase inhibitors that include Inhibitor-1, DARPP-32, and G-substrate.19–21 These proteins function as inhibitors in that phosphorylation results in the formation of a “competitive inhibitor” that binds to the phosphatase catalytic subunit denying the binding of phosphoprotein substrates. CPI-17 is of great interest in smooth muscle contraction for several reasons: first, its phosphorylation is catalyzed by PKC, which is activated in response to contractile agonist-dependent activation of PLC by diacylglycerol and increases in [Ca2+]i.22 In fact, it has long been known that PKC activation mediates slow smooth muscle contraction with no increase in [Ca2+]i or even diminishing levels of [Ca2+]i. Second, CPI-17 is abundant in smooth muscle tissues although it is not universally expressed in all smooth muscle.22 And finally, ROK and perhaps other kinases such as those mentioned above that catalyze the phosphorylation of MYPT1 in intact SMC also phosphorylate CPI-17. Thus, it appears that the SMC has 2 independent pathways originating at agonist receptor activation that lead to the phosphorylation of 2 proteins, MYPT1 and CPI-17, that inhibit MLCP activity.

The obvious question becomes, why 2 pathways that, in many cases, exist together within the same cell? Dimopoulos et al15 attempted to answer this question by examining the time courses for CPI-17 and MYPT1 phosphorylation and the correlation of these biochemical events with calcium sensitization. What they found was that CPI-17 phosphorylation proceeded more rapidly following agonist receptor engagement than did MYPT1 phosphorylation. CPI-17 phosphorylation was highly correlated with the rapid release of stored Ca2+ whereas MYPT1 phosphorylation was more dependent on the slower uptake and refilling of Ca2+ stores. Thus, the different pathways leading to MLCP inhibition are essentially controlling the kinetics of tension development. These are interesting and potentially significant findings. Other support for this concept may also be taken from the observations that MYPT1 and CPI-17 demonstrate uneven expression in smooth muscle tissues; generally, MYPT1 is more highly expressed in phasic smooth muscle whereas CPI-17 is more highly expressed in tonic smooth muscle.22 Rapid phosphorylation of CPI-17 may be important to achieve high levels of MLC phosphorylation needed for sustained tension in the face of declining [Ca2+]i observed in tonic smooth muscle, whereas MYPT1 phosphorylation would be important in sustaining MLC phosphorylation with rapidly changing ion channel activity seen in phasic smooth muscle.

However, there is another aspect to the role of these 2 pathways regulating MLCP, and that is the process of “calcium desensitization.” It has long been known that relaxation of agonist-contracted smooth muscle by NO-containing vasodilators is more efficient than relaxation of depolarized smooth muscle tissue. NO mediates SMC relaxation by increasing the levels of cyclic GMP that, in turn, activate PKG. In SMC, PKG is known to lower [Ca2+]i by activating calcium-dependent potassium channels, inhibiting agonist-dependent activation of PLC, stimulating Ca2+ uptake into the sarcoplasmic reticulum (SR) and inhibiting inositol trisphosphate (IP3)-mediated Ca2+ release from the SR (see 23 for a review). As illustrated in Figure 1, cGMP, via PKG-Iα activation, also activates MLCP. Surks et al12 demonstrated that the PKG-Iα isoform binds to what turns out to be the spliced out variant of MYPT1 that contains the C-terminal leucine zipper domain (LZ+) thereby targeting the kinase in an appropriate position to catalyze MYPT1 phosphorylation. The importance of this finding was demonstrated by Wooldridge et al24 where PKG-I catalyzes the phosphorylation of serine-695 of MYPT1. Recall that calcium-sensitizing kinases (ROK, ZIPK) inhibit MLCP in part at least through phosphorylation of T696. According to the model published by these latter authors, S695 phosphorylation and T696 phosphorylation cannot occur together because of steric exclusion. Thus, S695 phosphorylation prevents phosphorylation of T696 thus blocking MLCP inhibition. Fisher, Brozovich and coworkers10,11 demonstrated that NO/cGMP-dependent relaxation of smooth muscle was highly correlated with the expression of the spliced-out LZ+ isoform of MYPT1, which binds PKG-I. Thus, one possible outcome for having two separate pathways for the regulation of MLCP is to have at least one pathway available for calcium desensitization.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Calcium sensitization and calcium desensitization pathways converge on MLCP in smooth muscle. MLCP exists in an inactive (MLCPI) or an active (MLCPA) state depending on the phosphorylation of either CPI-17 or MYPT1. Calcium sensitization promotes CPI-17 and MYPT1 phosphorylation (shown here by phosphorylation of threonine-696, T696) by activation of protein kinases such as PKC and ROK. CPI-17 phosphorylation proceeds on a faster time course associated with the rapid generation of cross-bridge cycling and force development; MYPT1 phosphorylation, on the other hand, develops more slowly and is associated with the maintenance of force development. In both cases, MLCP activity is diminished even as [Ca2+]i is declining to maintain MLC phosphorylation. Calcium desensitization, on the other hand, is dependent on activation of PKG, and possibly cAMP-dependent protein kinase (PKA). PKG activation results in PP2A-dependent dephosphorylation of CPI-17 and activation of MLCP, and the phosphorylation of S695 of the LZ+ isoform of MYPT1. This prevents ROK-dependent phosphorylation of T696 resulting in the activation of MLCP. Because the expression of CPI-17 and the LZ+ isoform of MYPT1 varies from tissue to tissue, the sensitization of Ca2+-dependent contraction will also vary from tissue to tissue, thereby creating the opportunity for fine-tune control of smooth muscle tone in different tissues. Abbreviations: MLCP, myosin light chain phosphatase; CPI-17, MLCP inhibitor; MYPT1, MLCP targeting subunit; LZ+, spliced-out isoform of MYPT1 containing the C-terminal leucine zipper domain; PKC, protein kinase C; ROK, RhoA-activated kinase; PKG, cGMP-dependent protein kinase; PP2A, protein phosphatase 2A.

On the other hand, what is known about calcium desensitization and CPI-17? At least 2 laboratories have demonstrated that PKG activation leads to the dephosphorylation of CPI-17.25,26 Bonnevier and Arner26 found that the mere activation of PKC under conditions where Ca2+ levels were not increased in skinned smooth muscle preparations led to contractions that were attenuated by cGMP and PKG activation. Relaxation was entirely dependent on PKG-dependent dephosphorylation of CPI-17, presumably through the activation of a protein phosphatase 2A (PP2A). Thus, both MYPT1-T696 phosphorylation and CPI-17 phosphorylation are attenuated in calcium desensitization.

The regulation of MLC dephosphorylation through distinct signaling pathways is but one more example of redundancy for the regulation of a highly complex and important physiological process. As shown by Dimopoulos et al,15 one outcome of this redundancy may be to fine-tune the contractile process in different tissues. This could be true for both calcium sensitization and calcium desensitization. Yet, it is also possible that these pathways really do represent “back-up” systems so that changes in expression of one or more of these components during development, physiological stress, or even disease do not compromise the control of smooth muscle tone which is so important for vascular function, breathing, digestion and reproduction.

Acknowledgments

Sources of Funding

Supported by grants from the NIH (HL053426, HL066164).

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Morgan JP, Morgan KG. Vascular smooth muscle: the first recorded Ca2+ transients. Pflugers Arch. 1982; 395: 75–77.
    OpenUrlCrossRefPubMed
  2. ↵
    Schultz KD, Schultz K, Schultz G. Sodium nitroprusside and other smooth muscle relaxants increase cyclic GMP levels in rat ductus deferens. Nature. 1977; 265: 750–751.
    OpenUrlCrossRefPubMed
  3. ↵
    Katsuki S, Arnold WP, Murad F. Effects of sodium nitroprusside, nitroglycerin and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. J Cyclic Nucleo Res. 1977; 3: 239–247.
    OpenUrl
  4. ↵
    Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol. 2002; 34: 1345–1356.
    OpenUrlCrossRefPubMed
  5. ↵
    Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, Lu MM, Owens GK, Parmacek MS. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol. 2003; 23: 2425–2437.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem. 2001; 276: 4527–4530.
    OpenUrlFREE Full Text
  7. ↵
    Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol. 2006; 68: 345–374.
    OpenUrlCrossRefPubMed
  8. ↵
    Hartshorne DJ, Ito M, Erdodi R. Role of protein phosphatase type 1 in contractile functions: myosin phosphatase. J Biol Chem. 2004; 279: 37211–37214.
    OpenUrlFREE Full Text
  9. ↵
    Velasco G, Armstrong C, Morrice N, Frame S, Cohen P. Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett. 2002; 527: 101–104.
    OpenUrlCrossRefPubMed
  10. ↵
    Khatri JJ, Joyce KM, Brozovich FV, Fisher SA. Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation. J Biol Chem. 2001; 276: 37250–37257.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Chen FC, Ogut O, Rhee AY, Hoit BC, Brozovich FV. Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMP-mediated vasodilatation. J Mol Cell Cardio. 2006; 41: 488–495.
    OpenUrlCrossRefPubMed
  12. ↵
    Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME. Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Iα. Science. 1999; 286: 1583–1587.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Huang QQ, Fisher SA, Brozovich FV. Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation. J Biol Chem. 2004; 279: 597–603.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G-proteins, kinases, and myosin phosphatase. Physiol Rev. 2003; 83: 1325–1358.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Dimopoulos GJ, Semba S, Kitazawa K, Eto M, Kitazawa T. Ca2+-dependent rapid Ca2+ sensitization of contraction in arterial smooth muscle. Circ Res. 2007; 100: 121–129.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999; 274: 37385–37390.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Muranyi A, Derkach D, Erdodi F, Kiss A, Ito M, Hartshorne DJ. Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: inhibitory effects and occurrence in A7r5 cells. FEBS Lett. 2005; 579: 6611–6615.
    OpenUrlCrossRefPubMed
  18. ↵
    Borman MA, MacDonald JA, Muranyi A, Hartshorne DJ, and Haystead TA. Smooth muscle myosin phosphatase-associated kinase induces Ca2+ sensitization via myosin phosphatase inhibition. J Biol Chem. 2002; 277: 23441–23446.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Stralfords P, Hemmings HC, Greengard P. Inhibitors of protein phosphatase-1: inhibitor-1 from bovine adipose tissue and a dopamine- and cAMP-regulated phosphoprotein of bovine brain are identical. Eur J Biochem. 1989; 180: 143–148.
    OpenUrlPubMed
  20. ↵
    Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 1999; 23: 435–437.
    OpenUrlCrossRefPubMed
  21. ↵
    Endo S, Suzuki M, Sumi M, Nairn AC, Morita R, Yamakawa K, Greengard P, Ito M. Molecular identification of human G-substrate, a possible downstream component of the cGMP-dependent protein kinase cascade in cerebellar Purkinje cells. Proc Natl Acad Sci U S A. 1999; 96: 2467–2472.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Woodsome TP, Eto M, Everett A, Brautigan DL, Kitazawa T. Expression of CPI-17 and myosin phosphatase correlates with Ca2+ sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. J Physiol (London). 2001; 535: 553–564.
    OpenUrlCrossRefPubMed
  23. ↵
    Lincoln TM, Dey N, Sellak H. Invited Review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001; 91: 1421–1430.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Wooldridge AA, MacDonald JA, Erdodi F, Ma C, Borman MA, Hartshorne DJ, Haystead TAJ. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of serine 695 in response to cyclic nucleotides. J Biol Chem. 2004; 279: 34496–34504.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Etter EF, Eto M, Wardle RL, Brautigan DL, Murphy RA. Activation of myosin light chain phosphatase in intact arterial smooth muscle during nitric oxide-induced relaxation. J Biol Chem. 2001; 276: 34681–34685.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Bonnevier J, Arner A. Actions downstream of cGMP/protein kinase G can reverse protein kinase C-mediated phosphorylation of CPI-17 and Ca2+ sensitization in smooth muscle. J Biol Chem. 2004; 279: 28998–29003.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
January 5/19, 2007, Volume 100, Issue 1
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Myosin Phosphatase Regulatory Pathways
    Thomas M. Lincoln
    Circulation Research. 2007;100:10-12, originally published January 4, 2007
    https://doi.org/10.1161/01.RES.0000255894.25293.82

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Myosin Phosphatase Regulatory Pathways
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Myosin Phosphatase Regulatory Pathways
    Thomas M. Lincoln
    Circulation Research. 2007;100:10-12, originally published January 4, 2007
    https://doi.org/10.1161/01.RES.0000255894.25293.82
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured